Media
Anesiva's media center is designed to provide reporters with easy access to news about the company and its products for stories in development. If you don't find what you are looking for or need more information, please contact us.
Click here to download our most recent fact sheet.
|
|
 = Add Release to Briefcase |
| All Releases |
|---|
 |
Anesiva Initiates Phase 2 Trial with Adlea(TM) for Pain Relief Following Total Hip Replacement Surgery
Oct 4, 2007
|
13.1 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Oct 04, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that the first patient has been treated in a Phase 2 study of the company's compound Adlea(TM) (formerly 4975) for post-operative pain in patients who undergo total hip replacement surgery, also called Total Hip A...
|
|
|
Anesiva to Unveil Zingo(TM) Commercialization Plans
Oct 4, 2007
|
9.1 KB
|
| |
SOUTH SAN FRANCISCO, Oct 4, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it will host a briefing for the investment community to review the company's launch and commercialization plans for Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system. The briefing wil...
|
|
|
Anesiva Initiates New Phase 2 Trial of Adlea(TM) for Pain Relief Following Knee Replacement Surgery
Sep 13, 2007
|
12.3 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Sept 13, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced that it has initiated a new Phase 2 study of Adlea(TM) (formerly 4975) for the relief of post-operative pain in patients undergoing total knee replacement surgery, also called total knee arthroplasty (TKA). Adlea...
|
|
|
Anesiva to Present at BioCentury's NewsMakers in the Biotech Industry Conference on September 6, 2007
Aug 31, 2007
|
8.5 KB
|
| |
SOUTH SAN FRANCISCO, Calif., Aug 31, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) announced today that John P. McLaughlin, the company's chief executive officer, will present at BioCentury's Newsmakers in the Biotech Industry Conference in New York City on September 6, 2007 at 10:30 a.m. EDT.
To access the...
|
|
|
Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Aug 30, 2007
|
12.2 KB
|
| |
SOUTH SAN FRANCISCO, Calif., and OXFORD, England, Aug 30, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Anesiva, Inc. (Nasdaq: ANSV) and Particle Therapeutics Limited today announced that they have entered into an agreement granting Particle Therapeutics a specific-use license to incorporate Anesiva's drug delivery technology into its need...
|
|
|
